Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
about
Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in TaiwanNeuroendocrine differentiation: The mysterious fellow of colorectal cancerProtein kinase d as a potential chemotherapeutic target for colorectal cancer.Role of primary tumor resection among chemotherapy-treated patients with synchronous stage IV colorectal cancer: a survival analysisScreening of potential molecular targets for colorectal cancer therapy.Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin.A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model.Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastasesIn vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles.Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational studyPalliative treatment of unresectable metastatic colorectal cancer.Recently identified and potential targets for colon cancer treatment.Advances in cancer therapeutics and patient access to new drugs.Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Intra-arterial therapies for metastatic colorectal cancer.Non-operative therapies for colorectal liver metastases.The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.EMX2 gene expression predicts liver metastasis and survival in colorectal cancer.Geographic Variations and Time Trends in Cancer Treatments in TaiwanThe mechanisms of 5-FU-PLA-O-CMC-NPS-mediated inhibition of the proliferation of colorectal cancer cell line SW480.Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study.Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity.Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.Characterization of biological responses of colorectal cancer cells to anticancer regimens.The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.
P2860
Q24658652-B10C98CC-8B02-4A74-976D-3CC47FE079FEQ26778012-96311AEF-7379-48F5-B727-C8CCA4E7080EQ33606415-2CAD2C8A-1D2A-4CB7-86F9-ED6240654392Q33669034-597E39ED-E2D1-40FE-86F8-F6E55241C45DQ33735051-E938C2F6-8D19-4D57-8CD9-E39BD7F084DCQ33983663-1FFFF584-D91F-4135-A31A-162E6F8FB919Q34626926-471922E3-B4A6-492E-9592-15BB781C1206Q34702261-C26C76AE-EAB2-4F9B-9AD2-82FEB6733A85Q35606908-F6610E30-C0F0-488A-BA45-8C52567FE97AQ35666492-944D35DF-F40A-4F26-971E-0ECCC4025679Q36058816-86C4B2D2-8C09-490C-AD64-D21F22831A35Q36219923-84020510-A281-431D-A2B8-D8AAEAE9D802Q37007189-310E48EF-974A-445A-8082-52E0680DEE79Q37650308-46AD2174-4AC0-40E0-A511-4C005187564EQ37763104-58696D63-8958-4889-ACC5-DD888C3BB4A3Q37823895-1093CE5F-396A-41A1-B5AF-2BAE6FEFFF30Q38075848-860EFBAC-3A40-45B6-9B5E-6E93437033E8Q38179343-5D80785A-072E-47EE-9893-1CEE28187FD3Q38398883-3F86CC06-B94D-4600-92C2-FE54001E3C92Q38480031-0B2F7AE5-5BAA-4DE1-9DD0-5660C3659CC1Q38613759-C21CF092-55A1-4D08-ADBE-04B902D07F0AQ38646251-EAFAD696-0170-4D1B-BE85-1A468AAFF74AQ39003354-51DA253C-4A28-4A66-B0BF-42C9586F2ACBQ39608346-D930328B-9FF8-4B51-A31A-01507F31D278Q39642103-28BE883A-25E4-40A5-B6CA-5810AAE79E55Q39724222-243AC2BF-2541-4B95-AE61-EC8D694F6B57Q40074896-273D6C91-2FA9-4CDE-BCE1-D64CAB1AD9A7Q40446837-B25CBFC2-81A4-4842-A2B6-2C6E9DC25D02Q41911162-718D48EC-036F-4D3E-BA0B-8BA64372F002Q42434225-A2E6B922-8FCC-4C1C-A4ED-1558562CD660Q43411752-6B9702B9-BC24-4913-8B49-0014F0D15D54Q43421738-FAF156D2-AF1E-460C-B2F7-5338F8F9657EQ43597808-F5FCD7A9-7424-432F-A7FA-DBC81BA76F80Q51412952-BFA8975D-78C6-44D5-8F6E-9F9B7EF500EFQ52877939-AC6526FB-C65A-4555-9256-D0906CB33B44
P2860
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@en
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@nl
type
label
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@en
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@nl
prefLabel
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@en
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@nl
P1433
P1476
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
@en
P2093
Claus-Henning Köhne
P304
P356
10.1634/THEONCOLOGIST.2008-0202
P577
2009-05-01T00:00:00Z